Donor immune cells deployed in fight against tough childhood and adult cancers
NCT ID NCT05238792
Summary
This early-stage study is testing the safety of a new cell therapy for people with high-risk solid tumors that have come back or not responded to standard treatments. Doctors are giving patients specially trained immune cells (T cells) from healthy donors that are designed to recognize and attack multiple cancer proteins. The study will enroll both children (ages 6-17) and adults (ages 18-70) to find the safest dose of these cells, which may be given with or without a short course of chemotherapy first.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.